ARCHIVES

Isis 3521 Gets Fast-track Status For FDA Review.

This article is from The Cancer Letter archive.

Vol. 26 No. 44 | December 1, 2000

Download PDF Visit The Full Archive

Related Articles

Clinical Practice Guidelines Don’t Meet IOM Standards

June 26, 2013

In Brief: Salmon To Step Down As Center Director; Becker To Relinquish Positions At MDACC

September 4, 1998

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

House Passes Cancer Bill With Mandates for NCI

September 28, 2012

Tivozanib Does Not Improve OS Compared to Sorafenib

February 22, 2013

Appeals Court Overturns FDA Approval Of Generic Paclitaxel, A Setback For Ivax.

November 9, 2001